United BioSource Corporation is pleased to introduce Bracket, a Specialty Services provider dedicated to helping pharmaceutical sponsors and contract research organizations (CROs) achieve greater certainty and accurate outcomes in their clinical trials. Bracket combines two existing UBC businesses: UBC's Clinical Technologies Group and Specialty Clinical Services business. The company's goal in operating these formerly distinct business units as one cohesive business is to leverage the integration of science, technology and operational excellence and expand our portfolio of specialty products so they can best help customers optimize their research and development activities.
Bracket will continue to offer its pre-approval specialty solutions, including e-Clinical Technologies such as IVRS, ePRO, and eLearning as well as comprehensive Endpoint Reliability Solutions that incorporate Rater Training, Endpoint Adjudication, Ratings Surveillance, and Computerized Cognitive Testing.
The alignment of this breadth of capability is designed to address the new paradigm in clinical development: one that demands tools and analytics to optimize decision-making and ultimately provide greater precision. Although operating under a new and distinct public brand, Bracket will remain a UBC company.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.